Synthetic Carbohydrate Receptors (SCRs) are small molecules that can bind to N-glycans, which are prevalent on the surfaces of various pathogens, including viruses, bacteria, and cancer cells. By targeting N-glycans, SCRs have the potential to disrupt pathways central to the progression of many diseases, making them a promising therapeutic platform for treating a wide range of conditions. This project’s goal is to develop SCRs as broad-spectrum antiviral drugs and advance them through the drug-development pipeline. The project aims to demonstrate the efficacy of SCRs in treating a wide range of viral diseases, including endemic and pandemic viruses. If successful, the technology can also be applicable to treat bacterial infections and cancers.